Compare CubeSmart (CUBE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Neurocrine Biosciences Inc — how do they compare? CubeSmart trades at $37.66 (market cap $8.45B), while Neurocrine Biosciences Inc trades at $142.16 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and CubeSmart pays a 5.65% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Neurocrine Biosciences Inc for 23 Days on average.
| CUBE | NBIX | |
|---|---|---|
Market Cap | $8.45B | $14.36B |
Volume | 2,879,532 | 1,237,180 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $185.50 |
52-Week Low | $35.36 | $123.10 |
Typical Hold Time | 89 Days | 23 Days |
Enterprise Value | $11.97B | $14.37B |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CUBE trades at $37.23, down 1.4% on the day, with a bearish technical signal and mixed earnings history including a Q2 2026 FFO miss. The company maintains strong profitability with a 29.41% net income margin and a 5.4% dividend yield, but faces headwinds from moderating revenue growth and high leverage.
The outlook is cautiously optimistic with a consensus price target of $44.00, though risks include elevated debt levels and sector oversupply. Upside hinges on operational improvements and a return to earnings growth in H2 2026 as guided.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
